Welcome New Corporate Partners

Please join us in welcoming the following new corporate partners contributing their support to the HBA mission.


IBM Watson Health
CEO: Ginni Rometty
IBM Watson Health is committed to building smarter health ecosystems. This means simpler processes, better care, faster breakthroughs and improved experiences for people around the world. We have the essential capabilities necessary to help our clients drive their digital transformations: deep industry expertise, data and analytics and actionable insights—underpinned by security and trust.

Portola Pharmaceuticals 
CEO: Scott Garland
Portola is a global biotechnology company charting a new course in the treatment of serious blood-related disorders. Our dedication to unconventional exploration and discovery has yielded unique proprietary medicines that fundamentally shift how patients with thrombotic and other hematologic disorders are treated. By combining our expertise and passion with a persistent focus on the discovery and development of novel compounds, we strive to make a significant impact on the lives of patients around the world.


Cambridge BioMarketing 
CEO: Ben Beckley
Founded in 2001, Cambridge BioMarketing is a U.S.-based communications agency specializing in rare orphan diseases with over 100 employees. Headquartered in Boston, MA with offices in Oakland, CA, Cambridge BioMarketing is an industry leader in orphan drug launches, advising pharmaceutical companies with an integrated focus on both traditional healthcare professional (HCP) programs and direct-to-patient work. In partnering with predominantly pharmaceutical and biotech customers, the agency’s goal is to bring physicians, specialists, and patient communities together on behalf of clients to transform human health in the face of devastating, under-appreciated disease states.

RxER Communications Corp 
CEO: Anne Arvizu, PharmD, FASCP, PCC
RxER Communications Corp helps small biotech rare-disease focused companies, build patient-focused, compliant, value-producing Medical Affairs departments through consulting, execution strategy, benchmarking, launch and audit readiness, process initiation and provision of assets and products such as business cases and c-suite slide decks. We customize proven organizational modeling to drive team growth and expansion that supports business growth and patient education. We believe in and support the HBA's efforts to shatter ceilings and create gender parity within our industry and have created a proprietary leadership development training system for women executives in healthcare that we call Corecentryx®.


Xeris Pharmaceuticals 
CEO name: Paul Edick
Xeris is a specialty pharma company specializing in developing and commercializing ready to use liquid stable injectables.

Interested in becoming a corporate partner? Explore the value of partnership with the HBA and view the latest packages.